Categories Earnings, Finance

Qudian beats in Q2 despite slowdown in Chinese economy

Chinese fintech firm Qudian (NYSE: QD) on Friday reported second-quarter results that were better than the street projection, sending its shares up 4.7% immediately following the announcement. On an adjusted basis, earnings came in at 59 cents per share, 8 cents higher than expected.

Despite the slowdown in the Chinese economy, Qudian reported flat year-over-year revenues at around $323.5 million. The topline was boosted by a 12% increase in the number of registered users and partly offset by the discontinuation of Dabai Auto.

READ: JD.com reports massive earnings beat in Q2

CEO Min Luo said, “Since we have an overwhelming demand situation, instead of increasing marketing spend we have stepped up efforts to activate more new users in our loan book business. Through our increased efforts in credit trials and our evolving credit assessment system, new active borrowers increased by 107.9% from last quarter.”

Total outstanding loan balance at the end of the second quarter rose 91.8% to RMB28.7 billion.

Qudian also maintained its adjusted net income guidance for FY19 at above RMB 4.5 billion, which will represent a 76.5% increase from 2018.

READ: Sogou stock falls on weak guidance

Notably, Qudian is one of the few US-listed Chinese firms that have performed relatively well in the backdrop of US-China trade spat as well as a slowing economy back home. The stock has doubled since the beginning of this year, but is still considered underpriced by a margin of 10%.

The Xiamen-based firm owes its initial success to the opening up of the online credit market in China, allowing companies to set up digital platforms for small consumer credit products. However, last year the sector came under stringent regulatory scrutiny, resulting in curbs on such companies.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top